ASGE Interventional IBD: Management of Complications (On-Demand)| March 2022-Evolving Endpoints in IBD

Video Transcription

Video Summary

Dr. Reena Khanna, a gastroenterologist in London, Canada, discusses the use of different targets in the treatment of inflammatory bowel disease (IBD) in a presentation. She highlights the importance of treat-to-target strategies and the need to understand the operating properties of various targets. Dr. Khanna explains that symptoms alone are not reliable indicators of disease activity and do not correlate with mucosal healing. She discusses the use of biomarkers such as CRP and fecal calprotectin, noting their limitations and appropriate contexts for their use. Dr. Khanna also emphasizes the significance of endoscopy in assessing mucosal healing and the use of indices like the SESCD and Mayo score. She mentions the potential of imaging techniques and histology in assessing transmural healing and inflammation but notes that further validation is needed. Dr. Khanna concludes by highlighting the importance of outcome measure validation in IBD research and the need for standardized reporting across endoscopists and pathologists. The transcription of this video presentation is credited to Dr. Reena Khanna.

Asset Subtitle

Reena Khanna, MD

Keywords

inflammatory bowel disease

treat-to-target strategies

mucosal healing

biomarkers

endoscopy

validation